Advantageous biological effect, Cesium-131’s short half-life, and new shielded or dynamically modulated sources: Dr. Mark Rivard’s thoughts on brachytherapy from ABS 2018

As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types.

IsoRay Names Jonathan Hunt New Chief Financial Officer

RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Jonathan Hunt has been named Chief Financial Officer...

The value of Cesium for brachytherapy treatment lies in its short half-life for Dr. R. Alex Hsi Dr. R. Alex Hsi is a Radiation Oncologist at the Peninsula Cancer Center in Poulsbo, Washington. As a practitioner of various prostate radiation treatments like external beam radiation and stereotactic body radiation...

Nearly out of treatment options, Cesium-131 brachytherapy saved Barbara’s life

Dr. John Sheldon brought his experience with brachytherapy to bear with a targeted treatment for Barbie after her cervical cancer returned in 2015.

Biological effectiveness dose and convenience: Why Cesium-131 is the LDR brachytherapy isotope of choice for Dr. Bradley Prestidge.

Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the American Brachytherapy Society 2018 Annual Meeting, Dr. Prestidge shared with us his opinion on brachytherapy’s top...

Recent News

Cs-131 is a favorable isotope for use across a wide range of tumors and its dose distribution properties facilitate easy calculation and use in the clinic. Dr. Voichita Bar-Ad

Thomas Jefferson University Hospital

Find A Cesium Pioneer Near You

Doctors going above and beyond against the fight with cancer.
Learn More

All News

Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates

“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.